Key PointsSTAAR Surgical is the leading maker of implantable ocular lenses (IOL) used for cataract surgery.Its EVO ICL sales hit the highest levels in the United States in Q1 2024 since its FDA approval in March 2022.With over 90% of people over 65 years of age developing cataracts, STAAR Surgical has a long runway for growth from the aging population.5 stocks we like better than STAAR SurgicalSTAAR Surgical Co. NASDAQ: STAA develops and manufactures intraocular lenses (IOL) used to replace a person's natur ...

Alcon (ALC) is likely to grow in the coming quarters, backed by the flourishing Surgical business with its diversified portfolio and innovative technologies. Strength in the Vision Care business will further fuel growth. Strong, stable solvency also appears encouraging. Meanwhile, headwinds, such as macroeconomic impacts and the fiercely competitive industry, remain concerns for Alcon’s operations.  In the past year, this Zacks Rank #3 (Hold) stock has increased 17.7% compared with the 9.7% rise of the indu ...

Alcon’s (ALC) AcrySof IQ Vivity and Clareon Vivity extended depth of focus (EDOF) intraocular lenses (IOLs) have recently surpassed more than one million implants worldwide. The company’s revolutionary presbyopia-correcting intraocular lens (PCIOL) option has expanded the patient candidacy pool by addressing the diverse vision needs of patients who desire less dependency on glasses post-surgery and low visual disturbances.The recent development will strongly boost the company’s Surgical business, which offe ...

FORT WORTH, Texas--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today proudly announces AcrySof® IQ Vivity® and Clareon® Vivity extended depth of focus (EDOF) intraocular lenses (IOLs) have surpassed more than one million implants worldwide. Vivity is the most implanted EDOF IOL globally.1* Alcon is the global leader in IOLs—every four seconds an eye is implanted with an Alcon IOL—and continues to innovate in this space to address patient ...

Alcon, Inc. (NYSE:ALC) Q4 2023 Earnings Conference Call February 28, 2024 5:30 PM ET Company Participants Daniel Cravens - Vice President and Global Head, Investor Relations David Endicott - Chief Executive Officer Tim Stonesifer - Chief Financial Officer Conference Call Participants Veronika Dubajova - Citi Ryan Zimmerman - BTIG Susannah Ludwig - Bernstein Anthony Petrone - Mizuho Group David Saxon - Needham & Company Larry Biegelsen - Wells Fargo Brett Fishbin - KeyBanc Capital Markets Tom Stephan - Stife ...

Alcon, Inc. (ALC) delivered core earnings per share (EPS) of 70 cents in the fourth quarter of 2023, up 66.7% from the year-ago quarter’s figure (up 78% at the constant exchange rate or CER). The figure topped the Zacks Consensus Estimate by 2.9%. Alcon’s “core” results are based on non-IFRS (International Financial Reporting Standards) measures.In the fourth quarter, the company’s diluted EPS was 86 cents compared to a loss of 20 cents per share in the prior-year quarter.For the full year, the core EPS was ...

For the quarter ended December 2023, Alcon (ALC) reported revenue of $2.33 billion, up 8.2% over the same period last year. EPS came in at $0.70, compared to $0.42 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $2.34 billion, representing a surprise of -0.22%. The company delivered an EPS surprise of +2.94%, with the consensus EPS estimate being $0.68.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they com ...

GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and twelve months ended December 31, 2023. For the fourth quarter of 2023, sales were $2.3 billion, an increase of 8% on a reported basis and 10% on a constant currency basis(1), as compared to the same quarter of the previous year. Alcon reported diluted earnings per share of $0.86 and core diluted earnings per share(2) of $0.70 in the fourth quarter of 2023. David J. Endicott, Alco ...

Alcon (ALC) faces cost pressure amid a challenging macroeconomic environment. Also, a tough competitive landscape is a threat. The stock carries a Zacks Rank #4 (Sell).Alcon is experiencing inflationary pressure in electronic components, freight, labor, resins and plastics, which impact the company’s margins. The company is also encountering supply chain challenges in certain components, including microchips, resins and plastics, metals and filters.Further, the ophthalmology industry is highly competitive a ...

ALCON INC. INTERIM FINANCIAL REPORT INDEX Page Operating Performance 2 Liquidity and Capital Resources 11 Condensed Consolidated Interim Financial Statements of Alcon Inc. (unaudited) Consolidated Income Statement 15 Consolidated Statement of Comprehensive Income/(Loss) 16 Consolidated Balance Sheet 17 Consolidated Statement of Changes in Equity 18 Consolidated Statement of Cash Flows 19 Notes to Condensed Consolidated Interim Financial Statements of Alcon Inc. 20 Supplementary Information – Definitions and ...